Uterine sarcoma in the south of Israel: Study of 36 cases

✍ Scribed by Piura, Benjamin; Rabinovich, Alex; Yanai-Inbar, Ilana; Cohen, Yoram; Glezerman, Marek

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 99 KB
• Volume: 64
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199701)64:1<55::aid-jso11>3.0.co;2-v

✦ Synopsis

Background:

Uterine sarcomas are rare, charaterized by rapid clinical progression and poor prognosis, and their management has been a challenge. the purpose of this study was to investigate the clinical and histologic findings, treatment, and outcome of patients with uterine sarcoma in the south of israel.

Methods:

Data from the files of 36 patients with uterine sarcoma who were managed at the soroka medical center between january 1961 and december 1994 were evaluated.

Results:

The 5-year survival rate was 32% overall; 63% for 9 patients with endometrial stromal sarcoma (ess). 30% for 14 patients with mixed mesodermal sarcoma (mms) and 18% for 13 patients with leiomyosarcoma (lms): 41% for 22 patients with stage i and 19% for 14 patients with stages ii, iii, and iv. only the difference in the 5-year survival rate between ess and lms was statistically significant (p < 0.05). eleven patients (30.6%) were treated with surgery alone, 4 (11.1%) with surgery followed by pelvic radiotherapy, 11 (30.6%) with surgery followed by chemotherapy, 8 (22.2%) with surgery followed by pelvic radiotherapy and chemotherapy, one (2.8%) with chemotherapy alone, and one (2.8%) had no treatment.

Conclusions:

Uterine sarcomas are aggressive tumors with a poor prognosis. the treatment is surgery generally followed by adjuvant pelvic radiotherapy and/or systemic chemotherapy.